Shijiazhuang Yiling Pharmaceutical Co., Ltd. (SHE: 002603)

Shijiazhuang Yiling Pharmaceutical Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	907.31	940.51	1,904	995.26	1,337	733.41
Trading Asset Securities	9	205.97	518.38	55.27	216.97	292.73
Cash & Short-Term Investments	916.31	1,146	2,423	1,051	1,554	1,026
Cash Growth	-29.98%	-52.68%	130.61%	-32.40%	51.44%	-30.85%
Accounts Receivable	3,088	2,596	2,178	2,361	1,756	2,383
Other Receivables	26.15	0.23	0.97	4.73	18.27	41.32
Receivables	3,114	2,597	2,179	2,366	1,775	2,424
Inventory	1,941	2,459	2,022	1,673	1,580	1,222
Prepaid Expenses	-	94.11	0.9	39.39	37.04	0.09
Other Current Assets	212.59	247.81	630.17	473.65	513.54	395.87
Total Current Assets	6,184	6,544	7,254	5,602	5,459	5,068
Property, Plant & Equipment	7,333	7,311	6,229	5,758	4,313	3,060
Long-Term Investments	1,657	1,651	1,349	1	1	1
Goodwill	111.07	115.75	-	-	-	-
Other Intangible Assets	721.23	743.52	724.01	660.5	480.41	464.98
Long-Term Deferred Tax Assets	147.52	183.58	284.43	117	137.77	68.09
Long-Term Deferred Charges	221.45	189.37	107.16	239.33	261.17	299.54
Other Long-Term Assets	239.64	241.39	392.65	527.03	839.62	107.25
Total Assets	16,614	16,979	16,341	12,905	11,492	9,069
Accounts Payable	2,548	2,847	2,061	1,621	1,188	506.77
Accrued Expenses	206.08	419.64	644.78	269.71	306.97	162.72
Short-Term Debt	600.29	600.35	500.35	702.48	270.18	50.05
Current Portion of Long-Term Debt	3.02	201.12	150.12	-	-	-
Current Portion of Leases	-	5.5	5.86	13.43	-	-
Current Income Taxes Payable	90.13	42.45	242.15	11.38	59.4	13.48
Current Unearned Revenue	173.51	287.52	1,106	301.56	354.74	46.2
Other Current Liabilities	316.68	43.58	140.35	40.7	59.21	27.22
Total Current Liabilities	3,938	4,447	4,850	2,960	2,239	806.43
Long-Term Debt	667.1	599.1	200.15	500.47	-	-
Long-Term Leases	20.69	13.01	14.97	12.53	-	-
Long-Term Unearned Revenue	375.59	352.37	335.02	357.84	328.09	310.42
Long-Term Deferred Tax Liabilities	127.3	130.14	10.24	1.39	2.02	-
Total Liabilities	5,128	5,541	5,411	3,833	2,569	1,117
Common Stock	1,671	1,671	1,671	1,671	1,204	1,204
Additional Paid-In Capital	2,343	2,343	2,343	2,343	2,932	2,932
Retained Earnings	7,496	7,443	6,926	5,065	4,915	3,935
Treasury Stock	-	-	-	-	-122.15	-122.15
Comprehensive Income & Other	-6.06	-6.61	-7.22	-9.71	-9.08	-3.87
Total Common Equity	11,504	11,450	10,932	9,069	8,919	7,944
Minority Interest	-18.2	-11.73	-1.95	3.04	4.09	8.13
Shareholders' Equity	11,486	11,438	10,930	9,072	8,923	7,953
Total Liabilities & Equity	16,614	16,979	16,341	12,905	11,492	9,069
Total Debt	1,291	1,419	871.45	1,229	270.18	50.05
Net Cash (Debt)	-374.79	-272.6	1,551	-178.37	1,284	976.09
Net Cash Growth	-	-	-	-	31.52%	-34.23%
Net Cash Per Share	-0.22	-0.16	0.93	-0.11	0.77	0.59
Filing Date Shares Outstanding	1,671	1,671	1,671	1,671	1,667	1,667
Total Common Shares Outstanding	1,671	1,671	1,671	1,671	1,667	1,667
Working Capital	2,246	2,097	2,404	2,642	3,221	4,262
Book Value Per Share	6.89	6.85	6.54	5.43	5.35	4.77
Tangible Book Value	10,672	10,590	10,208	8,409	8,439	7,479
Tangible Book Value Per Share	6.39	6.34	6.11	5.03	5.06	4.49
Buildings	-	5,407	4,353	3,620	2,997	2,773
Machinery	-	3,098	2,484	2,005	1,499	1,312
Construction In Progress	-	1,471	1,574	1,950	1,371	317.07

Source: S&P Capital IQ. Standard template. Financial Sources.